PET/CT imaging
PET/CT imaging is an intervention with 26 clinical trials. Currently 8 active trials ongoing. Historical success rate of 90.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
2
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
81.8%
9 of 11 finished
18.2%
2 ended early
8
trials recruiting
26
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
PET Fibrin Imaging of DVT and PE
Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study
Pediatric PET/MR Image Registry
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Clinical Trials (26)
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
PET Fibrin Imaging of DVT and PE
Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study
Pediatric PET/MR Image Registry
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
FDG PET/MR Imaging of Peripheral Pain Generators
Lung Nodule Detection Using Ultra-long FOV PET/CT
Observation Study for Prediction of Allograft Survival and Impact of Imaging in Kidney Transplant Recipients.
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Feasibility of PET/CT to Detect the Oral/Pulmonary Distribution of Nicotine Following E-cigarette Use
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
Optimising Molecular Radionuclide Therapy
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in HNC Patients Using PET/CT
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Verification of Imaging System PCD-1000A
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 26